Literature DB >> 23044416

Fibroblast growth factor 2 inhibits up-regulation of bone morphogenic proteins and their receptors during osteoblastic differentiation of human mesenchymal stem cells.

Emmanuel Biver1, Anne-Sophie Soubrier, Cyril Thouverey, Bernard Cortet, Odile Broux, Joseph Caverzasio, Pierre Hardouin.   

Abstract

Understanding the interactions between growth factors and bone morphogenic proteins (BMPs) signaling remains a crucial issue to optimize the use of human mesenchymal stem cells (HMSCs) and BMPs in therapeutic perspectives and bone tissue engineering. BMPs are potent inducers of osteoblastic differentiation. They exert their actions via BMP receptors (BMPR), including BMPR1A, BMPR1B and BMPR2. Fibroblast growth factor 2 (FGF2) is expressed by cells of the osteoblastic lineage, increases their proliferation and is secreted during the healing process of fractures or in surgery bone sites. We hypothesized that FGF2 might influence HMSC osteoblastic differentiation by modulating expressions of BMPs and their receptors. BMP2, BMP4, BMPR1A and mainly BMPR1B expressions were up-regulated during this differentiation. FGF2 inhibited HMSCs osteoblastic differentiation and the up-regulation of BMPs and BMPR. This effect was prevented by inhibiting the ERK or JNK mitogen-activated protein kinases which are known to be activated by FGF2. These data provide a mechanism explaining the inhibitory effect of FGF2 on osteoblastic differentiation of HMSCs. These crosstalks between growth and osteogenic factors should be considered in the use of recombinant BMPs in therapeutic purpose of fracture repair or skeletal bioengineering.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23044416     DOI: 10.1016/j.bbrc.2012.09.129

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  [Experimental study on accelerated healing of jaw fracture using gelatin sponge compound growth factor].

Authors:  Tang Yanfeng; Chen Jianlin; Zhou Yunbiao
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-10-01

2.  Bone morphogenetic protein is required for fibroblast growth factor 2-dependent later-stage osteoblastic differentiation in cranial suture cells.

Authors:  Taoran Jiang; Shengfang Ge; Yoong Hoon Shim; Ce Zhang; Dejun Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Osteoblast Differentiation and Bone Matrix Formation In Vivo and In Vitro.

Authors:  Harry C Blair; Quitterie C Larrouture; Yanan Li; Hang Lin; Donna Beer-Stoltz; Li Liu; Rocky S Tuan; Lisa J Robinson; Paul H Schlesinger; Deborah J Nelson
Journal:  Tissue Eng Part B Rev       Date:  2016-12-27       Impact factor: 6.389

4.  Comparison of Mesenchymal Stem Cell Source Differentiation Toward Human Pediatric Aortic Valve Interstitial Cells within 3D Engineered Matrices.

Authors:  Bin Duan; Laura A Hockaday; Shoshana Das; Charlie Xu; Jonathan T Butcher
Journal:  Tissue Eng Part C Methods       Date:  2015-04-13       Impact factor: 3.056

5.  Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.

Authors:  Nandina Paria; Tae-Joon Cho; In Ho Choi; Nobuhiro Kamiya; Kay Kayembe; Rong Mao; Rebecca L Margraf; Gerlinde Obermosser; Ila Oxendine; David W Sant; Mi Hyun Song; David A Stevenson; David H Viskochil; Carol A Wise; Harry K W Kim; Jonathan J Rios
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

6.  Combined effects of simvastatin and fibroblast growth factor-2 on the proliferation and differentiation of preosteoblasts.

Authors:  Jun-Beom Park
Journal:  Biomed Rep       Date:  2013-07-17

Review 7.  Mesenchymal stem cells for treating autoimmune dacryoadenitis.

Authors:  Xiaoxiao Lu; Xilian Wang; Hong Nian; Dan Yang; Ruihua Wei
Journal:  Stem Cell Res Ther       Date:  2017-06-05       Impact factor: 6.832

8.  Vascularization converts the lineage fate of bone mesenchymal stem cells to endothelial cells in tissue-engineered bone grafts by modulating FGF2-RhoA/ROCK signaling.

Authors:  Donglin Li; Pengzhen Cheng; Huijie Jiang; Tianqing Cao; Jimeng Wang; Yi Gao; Yangjing Lin; Chunmei Wang; Shuaishuai Zhang; Junqin Li; Bin Liu; Yue Song; Liu Yang; Guoxian Pei
Journal:  Cell Death Dis       Date:  2018-09-20       Impact factor: 8.469

9.  Distinct effects of RGD-glycoproteins on Integrin-mediated adhesion and osteogenic differentiation of human mesenchymal stem cells.

Authors:  Elisabeth H Schwab; Maria Halbig; Kristina Glenske; Alena-Svenja Wagner; Sabine Wenisch; Elisabetta A Cavalcanti-Adam
Journal:  Int J Med Sci       Date:  2013-11-09       Impact factor: 3.738

10.  Regulation of vascular smooth muscle cell calcification by syndecan-4/FGF-2/PKCα signalling and cross-talk with TGFβ.

Authors:  Samantha J Borland; Thomas G Morris; Shona C Borland; Mark R Morgan; Sheila E Francis; Catherine L R Merry; Ann E Canfield
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.